Bedrijfsoverzicht
Cabaletta Bio, Inc. is a clinical-stage biotechnology entity dedicated to the discovery and development of engineered T cell therapies specifically designed for patients suffering from autoimmune diseases. The company operates within the broader Healthcare sector, focusing on the specialized Biotechnology industry where innovation in cellular medicine is critical for advancing patient treatment options. As of the latest reported data, the firm holds a market capitalization of $348.44M and employs a workforce of 154 individuals to support its research and development initiatives. The revenue figure for the trailing twelve months is not available in current disclosures, which is typical for clinical-stage companies that prioritize capital allocation toward product development over immediate commercial sales, thereby indicating a growth-oriented business model rather than a mature cash-generating operation.
Financiële gezondheid
The company reported a net income of $-167,856,000 and an EBITDA of $-170,595,008 for the trailing twelve months, while revenue data for the same period is unavailable, highlighting a significant cost structure dominated by research expenses and operational burn rather than profitability. This financial reality is underscored by a free cash flow position of $-81,283,128, which reflects a high consumption of cash resources necessary to sustain clinical trials and platform development before commercialization begins. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for biotechnology firms in the clinical stage that have not yet generated substantial sales revenue to calculate meaningful percentages. Despite these negative earnings figures, the balance sheet maintains a cash reserve of $133.60M against total debt of $27.10M, resulting in a debt-to-equity ratio of 24.18 that suggests a leveraged capital structure relative to equity but manageable given the asset-heavy nature of biotech R&D. The current ratio stands at 2.77, indicating that the company possesses sufficient liquid assets to cover its short-term liabilities multiple times over, providing a buffer against liquidity crises during expensive development phases. Furthermore, the return on equity is -127.0% and the return on assets is -61.5%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic of entities in the early phases of drug development seeking to achieve milestone valuations.
Waarderingsbeoordeling
Valuation multiples for Cabaletta Bio, Inc. present a complex picture due to the company's pre-commercial status, with a trailing P/E ratio listed as N/A and a forward P/E of -2.23, implying that analysts project earnings growth that is not yet realized or that the company is expected to transition from losses to profitability in the future. The price-to-book ratio is calculated at 2.81, suggesting that the market values the company at nearly three times its book value, which often reflects the high potential value of intellectual property and pipeline assets that are not fully captured on traditional accounting balance sheets. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA of -1.42 are provided as N/A or negative, indicating that traditional revenue-based valuation methods are less applicable until sales figures materialize. The stock has exhibited significant volatility, trading between a 52-week low of $1.06 and a 52-week high of $3.78, with the current market price positioned dynamically within this range based on daily trading activity. The beta coefficient is 3.29, a value that signifies the stock's price movements are highly sensitive to broader market shifts, exhibiting volatility more than three times that of the overall market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a clinical-stage entity where growth rates are not yet applicable in the traditional sense of expanding commercial operations. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A and 0.0% respectively, indicating that all available financial resources are being reinvested directly into research, development, and the advancement of the resecabtagene autoleucel pipeline rather than distributed to shareholders. This reinvestment strategy is essential for a biotechnology firm where success depends on completing clinical trials and securing regulatory approvals before any commercial revenue can be generated to fund operations. Consequently, the overall growth and income profile of Cabaletta Bio, Inc. is defined by capital appreciation potential driven by clinical milestones rather than dividend income or immediate revenue expansion.